{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:21Z","timestamp":1760189001265},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.3816\/clm.2006.n.059","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:11:07Z","timestamp":1221095467000},"page":"199-204","source":"Crossref","is-referenced-by-count":15,"title":["Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox"],"prefix":"10.3816","volume":"7","author":[{"given":"Kevin M.","family":"Chin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2006.n.059_bib1","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2003-04-1044","article-title":"Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma","volume":"102","author":"Yawalkar","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.059_bib2","first-page":"397","article-title":"The immunological profile of mycosis fungoides","volume":"50","author":"Jensen","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"10.3816\/CLM.2006.n.059_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/107327480100800213","article-title":"Infectious complications of cutaneous t-cell lymphoma","volume":"8","author":"Tsambiras","year":"2001","journal-title":"Cancer Control"},{"key":"10.3816\/CLM.2006.n.059_bib4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the Initials treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.059_bib5","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.n.059_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0889-8588(18)30061-3","article-title":"Chemotherapy for mycosis fungoides and the Sezary syndrome","volume":"9","author":"Rosen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2006.n.059_bib7","doi-asserted-by":"crossref","first-page":"11885","DOI":"10.1016\/S0021-9258(19)38482-0","article-title":"Structure\/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells","volume":"265","author":"Williams","year":"1990","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2006.n.059_bib8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1084\/jem.167.2.612","article-title":"Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxinrelated interleukin 2 fusion protein","volume":"167","author":"Bacha","year":"1988","journal-title":"J Exp Med"},{"key":"10.3816\/CLM.2006.n.059_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1749-6632.2001.tb03720.x","article-title":"Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma","volume":"941","author":"Foss","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.3816\/CLM.2006.n.059_bib10","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent earlystage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2006.n.059_bib11","first-page":"399","article-title":"Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2","volume":"91","author":"LeMaistre","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.059_bib12","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.2004.03.071","article-title":"Phase II study of denileukin diftitox for relapsed\/refractory B-cell non-Hodgkin's lymphoma","volume":"22","author":"Dang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.059_bib13","doi-asserted-by":"crossref","first-page":"722a","DOI":"10.1182\/blood.V104.11.2641.2641","article-title":"Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed\/refractory T-cell non-Hodgkin's lymphoma","volume":"104","author":"Dang","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.059_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.059_bib15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","article-title":"Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, Ontak) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication","volume":"1","author":"Foss","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2006.n.059_bib16","first-page":"29","article-title":"Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma","volume":"18","author":"Rook","year":"2002","journal-title":"Adv Dermatol"},{"key":"10.3816\/CLM.2006.n.059_bib17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0889-8588(03)00109-6","article-title":"Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2","volume":"17","author":"Rook","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2006.n.059_bib18","first-page":"37","article-title":"Pentostatin treatment of cutaneous T-cell lymphoma","volume":"14","author":"Dearden","year":"2000","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CLM.2006.n.059_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1749-6632.2001.tb03724.x","article-title":"Therapy of T cell lymphomas with pentostatin","volume":"941","author":"Kurzrock","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.3816\/CLM.2006.n.059_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10428199709109162","article-title":"2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders","volume":"26","author":"Kong","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.n.059_bib21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2006.n.059_bib22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1200\/JCO.2001.19.3.779","article-title":"Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides","volume":"19","author":"de Coninck","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.059_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and longterm outcome of patients with generalized patch and\/or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2006.n.059_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T07:51:14Z","timestamp":1631778674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1557919011703298"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.n.059","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}